Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 4
Author: KRChoksey

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA | BSE: 524715 | ISIN: INE044A01036 | Industry: Pharmaceuticals
| Expensive Performer

1751.5000 58.40 (3.45%)

NSE Apr 17, 2025 15:31 PM

27.18% Gain from 52W Low

Volume: 2.7M

Sun Pharmaceutical Industries Ltd.

13 Aug 2024

1751.50

3.45%

Global Specialty and IPM growth to continue to drive growth

Accumulate: Sun Pharmaceutical Industr...

Recommendation

KRChoksey

SUNPHARMA exceeded our profitability estimates by a huge margin for Q1FY25. The EBITDA exceeded by 12% and EBITDA margins by 391 bps from our estimates while GPMs exceeded the expectations marginally by 36 bps from our estimates for Q1FY25.

Sun Pharmaceutical I.. has an average target of 2054.00 from 8 brokers.

The Baseline | 17 Apr 2025, 05:29PM

Market closes higher, HDFC AMC's net profit beats Forecaster estimates by 8%

Trendlyne Marketwatch | 17 Apr 2025, 03:57PM

Change is hard, and some Indian pharma companies are embracing it better than others

| 09 Aug 2022